Esophageal Cancer
Pipeline by Development Stage
Drug Modality Breakdown
Esophageal Cancer is a $5.6B market that appears mature with limited primary-indication focused innovation.
Key Trends
- Severe data quality issue: all top 10 products listed have isPrimaryIndication=false, suggesting market data may not reflect true esophageal cancer-specific treatment landscape
- Heavy dominance by androgen receptor antagonists (46% share) and tyrosine kinase inhibitors (20% share), mechanisms typically associated with other cancers
- Robust clinical trial activity (332 trials across all phases) indicates ongoing research, though most pipeline appears experimental
Career Verdict
Proceed with caution—the market data integrity issue makes it difficult to assess true career opportunities; verify esophageal cancer-specific product portfolios before committing to specialization.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | XTANDI (enzalutamide) | Astellas | $2.6B | 46% | Peak | Stable | 10.7yr |
| 2 | CABOMETYX (cabozantinib) | Exelixis | $1.1B | 20% | Peak | Stable | 7.2yr |
| 3 | VERZENIO (abemaciclib) | Eli Lilly and Company | $757M | 14% | Peak | Stable | 5.3yr |
| 4 | LYNPARZA (olaparib) | AstraZeneca | $487M | 9% | Peak | Stable | 5.2yr |
| 5 | KISQALI (ribociclib) | Novartis | $371M | 7% | Peak | Stable | 9.9yr |
Drug Class Breakdown
dominant but off-indication usage
second-line mechanism
supportive agents
emerging precision oncology
growing immunotherapy focus
data incomplete
Career Outlook
StableEsophageal cancer represents a stable, mature oncology sub-market with 7,080 jobs but limited growth catalyst visibility. The market is dominated by off-indication products, suggesting the true esophageal cancer-specific pipeline may be smaller than reported data implies. Hiring remains steady across commercial, R&D, and clinical operations, but career growth will depend on navigating a crowded competitive landscape.
Breaking In
Entry-level candidates should target Commercial or Medical Affairs roles at large players (AstraZeneca, Takeda, Roche) where training infrastructure is strongest and off-indication product breadth creates mentorship opportunities.
For Experienced Professionals
Experienced professionals should seek Clinical Operations or Regulatory roles where salary premiums are highest ($307K+) and pipeline complexity (332 trials) creates demand for specialized expertise in GI oncology.
In-Demand Skills
Best For
Hiring Landscape
The esophageal cancer indication supports 7,080 jobs across 15 companies, with strong commercial hiring (1,128 roles) driven by marketing and sales roles in a mature market. AstraZeneca, Takeda, and Amgen lead hiring, but mid-size biotechs like Exelixis show concentrated opportunities. Clinical operations roles command the highest average salary ($307K), reflecting the complexity of ongoing trials.
Top Hiring Companies
By Department
Commercial roles dominate hiring and offer mid-tier salaries; clinical operations offers the highest compensation but fewer openings, making it a competitive niche for specialized expertise.
On Market (1)
Approved therapies currently available
Competitive Landscape
47 companies ranked by most advanced pipeline stage
+17 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 49 trials with date data
Clinical Trials (50)
Total enrollment: 12,462 patients across 50 trials
Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery
CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer
MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV
The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer
Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients
Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity
S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen
Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens
Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis
Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen
Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients
Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)
XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy
Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer
Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer
ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)
Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer
Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen
mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer
Pembrolizumab in Refractory Advanced Esophageal Cancer
Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms
Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer
Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer
Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
Health-related Quality of Life of Patients With Esophageal Cancer After Surgery
First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.
Peptide Vaccination in Treating Patients With Esophageal Cancer (STF-II)
Multicenter Study to Perioperative Chemotherapy for Resectable Adenocarcinoma in Gastric Cancer
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer
Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma
A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer
A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer
Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT
Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma
Sutent + Taxol for Advanced Esophageal Cancer
Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma
Related Jobs in Oncology
Key Account Manager, Oncology
Senior Virology Care Specialist
Sr. Biosample Manager
Oncology Account Manager, North Central
(Assoc.) Director, Clinical Development Scientist-Urologic Oncology
(Sr.) Medical Director, Oncology
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.